ANALOGS OF GALANIN(1-16) MODIFIED IN POSITIONS 1-3 AS LIGANDS TO RAT HYPOTHALAMIC GALANIN RECEPTORS

被引:4
作者
BAEZA, CR
KASK, K
LANGEL, U
BARTFAI, T
UNDEN, A
机构
[1] Department of Neurochemistry and Neurotoxicology, Stockholm University
来源
ACTA CHEMICA SCANDINAVICA | 1994年 / 48卷 / 05期
关键词
D O I
10.3891/acta.chem.scand.48-0434
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Structure-activity relationship (SAR) studies have revealed that the first three residues of galanin (Gly1-Trp2-Thr3) are of critical importance for high-affinity binding to the galanin receptor. Furthermore degradation studies have shown that galanin is easily cleaved to yield inactive fragments in rat hypothalamus (t1/2 = 100 min). To obtain galanin receptor ligands with long-lasting biological activity the amino-terminus of galanin must be protected. We have therefore synthesized analogs of rat galanin(1-16) carrying modifications at the three amino-termini of galanin. All modifications of the peptide backbone flanking Trp2 as in the analogs [N-Mc-Trp2]-galanin(1-16), [Tcc2]-galanin-(1-16), (Trp2-PSI[CH2NH]-Thr3)-galanin-(1-16) produced a dramatic loss of affinity toward the galanin receptor. [N-Me-Thr3]-galanin(1-16) was the most active of the peptide backbone modified analogs (K(D) = 997 +/- 1 nM). Modifications of the indole ring in Trp2{[For-Trp2]-galanin-(1-16), [Tcc2]-galanin-1-16)} yielded analogs which, at concentrations up to 10 muM, did not displace [I-125]galanin binding. N-Methylation of Gly1 by the introduction of sarcosine {[Sar1]-galanin(1-16)} did not significantly affect the ligand-binding properties of galanin(1-16) (K(D) = 8.7 +/- 0.1 nM).
引用
收藏
页码:434 / 438
页数:5
相关论文
共 36 条
[1]   PRESENCE OF GALANIN IN HUMAN PANCREATIC NERVES AND INHIBITION OF INSULIN-SECRETION FROM ISOLATED HUMAN ISLETS [J].
AHREN, B ;
ARRAJAB, A ;
BOTTCHER, G ;
SUNDLER, F ;
DUNNING, BE .
CELL AND TISSUE RESEARCH, 1991, 264 (02) :263-267
[2]   STRUCTURAL REQUIREMENT FOR GALANIN ACTION IN THE PANCREATIC BETA-CELL LINE RIN M-5F [J].
AMIRANOFF, B ;
LORINET, AM ;
YANAIHARA, N ;
LABURTHE, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 163 (01) :205-207
[3]  
BAEZA CR, 1992, INT J PEPT PROT RES, V39, P195
[4]   GALANIN AND GALANIN ANTAGONISTS - MOLECULAR AND BIOCHEMICAL PERSPECTIVES [J].
BARTFAI, T ;
FISONE, G ;
LANGEL, U .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (08) :312-317
[5]  
BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229
[6]  
BAUER FE, 1986, LANCET, V2, P192
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]   N-METHYLAMINO ACIDS IN PEPTIDE-SYNTHESIS .5. SYNTHESIS OF N-TERT-BUTYLOXYCARBONYL, N-METHYLAMINO ACIDS BY N-METHYLATION [J].
CHEUNG, ST ;
BENOITON, NL .
CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE, 1977, 55 (05) :906-910
[9]   SOLID-PHASE REDUCTIVE ALKYLATION TECHNIQUES IN ANALOG PEPTIDE-BOND AND SIDE-CHAIN MODIFICATION [J].
COY, DH ;
HOCART, SJ ;
SASAKI, Y .
TETRAHEDRON, 1988, 44 (03) :835-841
[10]  
COY DH, 1993, 13TH AM PEPT S EDM, P508